



BerGenBio ASA: Notice of Extraordinary General Meeting

Bergen, Norway, 16 December 2021 – Notice is hereby given that an Extraordinary General Meeting in BerGenBio ASA (OSE:BGBIO) will be held on 6 January 2022 at 10:00 hours (CET).

The notice, registration form and power of attorney are attached to this release. The notice will be sent to all registered shareholders and is available at <https://www.bergenbio.com/investors/general-meetings/>

All shareholders are encouraged to exercise their shareholder rights. Due to the ongoing corona virus pandemic, the Board encourages shareholders not to attend the general meeting in person, but rather to make use of the ability to vote by proxy. The proxy form is attached to this release and available on the Company's website: <https://www.bergenbio.com/investors/general-meetings/>

The following items are on the agenda: (i) Election of new Chair of the Board of Directors and changes to the board (ii) Remuneration to the chair of the board.

We encourage all shareholders to register as electronical user in VPS to save environment impact.

-Ends-

Contacts

Martin Olin, CEO, BerGenBio ASA
ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme focused on combination and single agent therapy in cancer and COVID-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is developing companion diagnostic tests to potentially identify patient populations most likely to benefit from AXL inhibition. This is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.